UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

---

Form 8-K

---

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 24, 2010

 

---

MTS SYSTEMS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Registrant’s telephone number, including area code: (952) 937-4000

 

N/A

(Former name or former address, if changed since last report.)

 

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

---

---

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(d)           Election of Directors.  On April 24, 2010, to be effective May 15, 2010, the Board of Directors of the Company elected Emily Maddox Liggett and William V. Murray to serve as a directors of the Company.  The Board of Directors plans to make committee assignments for Ms. Liggett and Mr. Murray at its meeting in May.

 

Ms. Liggett is currently the president and chief executive officer of Novatorque, Inc., a manufacturer of high-efficiency electric motor systems.  She is currently on the Board of Directors of Immersion Corporation and the Purdue University School of Engineering Advisory Board.  Prior to 2009, Ms. Liggett’s career experience includes president and chief executive officer positions at Apexon Inc., and Capstone Turbine Corporation.  She also served in various roles at Raychem Corporation.

 

Mr. Murray is currently the president and chief executive officer of ReShape Medical, Inc., an early stage medical device company developing a non-surgical treatment for obesity.  He is currently on the Biomedical Leadership Council  of Directors for OCTANe, an industry association.  Prior to 2008, Mr. Murray led his own business, Murray Consulting, Inc., and held senior executive positions at Applied Biosystems, Inc., VIASYS Healthcare, Inc., and Medtronic, Inc.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.